Search Results
Your search for ,wAS matches 27583 pages
Showing 18851 - 18900Enhanced Survival With Implantable Scaffolds That Capture Metastatic Breast Cancer Cells in Vivo
A small device implanted under the skin may improve breast cancer survival by catching cancer cells, slowing the development of metastatic tumors in other organs, and allowing time to intervene with surgery or other therapies. These findings, reported by Rao et al in Cancer Research, suggest a path ...
Specimen Margin Tops Frozen Margin as Prognostic Marker in Oral Cancer Surgery
Intraoperative frozen margins from the tumor bed help to assess the prognosis of oral cancer, but the permanent specimen margin remains king, according to a retrospective cohort study reported at the 9th International Conference on Head and Neck Cancer.1 Results indicated that the rate of local...
Testosterone Therapy May Be Cardioprotective in Patients Undergoing Chemotherapy
The anabolic hormone testosterone may lessen the early adverse cardiovascular effects of chemotherapy and chemoradiation for advanced or recurrent cancer, according to a randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1 Among the patients studied,...
Reducing Drug Costs by Increasing Science-Driven Drug Discovery
For several years now, the American health-care system has been undergoing a transformation. Innovative ideas are being explored, new systems continue to be created, and millions of lives have been impacted. As health-care providers and research engines, academic institutions have an opportunity...
ASCO and AACI Initiative to Reduce Administrative and Regulatory Burden in Cancer Clinical Trials
As reported in the Journal of Clinical Oncology, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, and colleagues have provided a summary of the groundwork of an initiative by ASCO and the Association of American Cancer Institutes (AACI) to identify and reduce...
Immune Checkpoint Inhibitors March to First-Line Treatment in Advanced NSCLC
For the majority of patients who are diagnosed with advanced-stage non–small cell lung cancer (NSCLC), platinum-based doublets have been the standard of care for over 30 years. Recently, the immune checkpoint inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) demonstrated superior survival ...
Decisional Regret After Initial Treatment Decisions Among Parents of Children With Cancer
Racial/ethnic minority parents were more likely to express regret about initial cancer treatment decisions for their children, according to a study reported in the Journal of Clinical Oncology. Mack et al found that factors associated with less decisional regret included receiving high-quality...
‘Encouraging Survival Outcomes’ Reported With Combined Nivolumab and Ipilimumab in Advanced Melanoma
Hodi et al found “encouraging survival outcomes” with the addition of nivolumab to ipilimumab in patients with previously untreated unresectable stage III or IV melanoma, according to 2-year overall survival data in the phase II CheckMate 069 trial. These results were reported in The...
First-Line Nivolumab Alone and Combined With Platinum-Based Chemotherapy in Advanced NSCLC
The phase I CheckMate 012 study examined the effects of nivolumab (Opdivo) monotherapy and nivolumab combined with platinum-based doublets as first-line treatments in patients with advanced non–small cell lung cancer (NSCLC). Encouraging efficacy and safety findings were reported in the Journal...
Adolescent Girls With Leukemia May Not Be Screened for Pregnancy Before Beginning Chemotherapy
A new study indicates that adolescent females with acute leukemia have low rates of pregnancy screening prior to receiving chemotherapy that can cause birth defects. These findings were published by Rao et al in Cancer. Although many chemotherapy drugs can cause birth defects, there are no...
Good Outcome Reported With Unrelated-Donor Cord Blood Transplantation in Patients With Minimal Residual Disease
Survival with hematopoietic cell transplantation (HCT) from unrelated cord-blood donors was at least as good as that with HLA-matched unrelated donors and better than that with HLA-mismatched unrelated donors in patients with acute leukemia or myelodysplastic syndrome who had pretransplantation...
Overall Survival With Everolimus in Advanced Pancreatic Neuroendocrine Tumors in the RADIANT-3 Trial
As reported by Yao et al in the Journal of Clinical Oncology, the final overall survival analysis from the phase III RADIANT-3 trial showed a median survival of 44.0 months among patients with advanced pancreatic neuroendocrine tumors initially randomized to receive everolimus (Afinitor, Zortress)...
CDC Finds Cancer Death Rates Among Children and Adolescents Declined by 20%, With Brain Cancer Topping Leukemia as Leading Cause of Death
New findings from the Centers for Disease Control and Prevention (CDC) show that the cancer death rate for children and adolescents aged 1 to 19 has been steadily declining since the mid-1970s and dropped by 20% from 1999 to 2014, the result of advances in therapy, especially for leukemia. During...
Joint Presence of Metabolic Syndrome and Obesity Seems to Be Associated With Poorer Survival in Early-Stage Colorectal Cancer
In a study in Kaiser Permanante patients reported in the Journal of Clinical Oncology, Cespedes Feliciano et al found that the joint presence of obesity and metabolic syndrome in those with early-stage colorectal cancer was associated with poorer overall and colorectal cancer–specific...
Study Suggests Role of Bilateral Oophorectomy in Preventing Premenopausal Breast Cancer in BRCA2- but Not BRCA1-Mutation Carriers
Bilateral oophorectomy was associated with prevention of premenopausal breast cancer in BRCA2- but not BRCA1-mutation carriers, according to a study reported by Kotsopoulos et al in the Journal of the National Cancer Institute. The study included 3,722 women with BRCA mutations in a prospective...
American Association for Cancer Research Releases 2016 Cancer Progress Report
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug...
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
A drop in the number of cancer cells detected in a patient’s blood could be the best indicator yet as to whether treatment for prostate cancer is working. A new study, published by Lorente et al in European Urology, shows that a 30% decline in a patient’s numbers of circulating tumor...
Everolimus Plus Bevacizumab Shows Activity in Advanced Non–Clear Cell Renal Cell Carcinoma
The combination of everolimus (Afinitor, Zortress) and bevacizumab (Avastin) was associated with clinical benefit in advanced non–clear cell renal cell carcinoma with a major papillary component, according to a single-center phase II trial reported by Voss et al in the Journal of Clinical...
Combined FISH and IHC Identifies Patients With NSCLC With Rare ALK Fusions That Respond to Crizotinib
The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non–small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to...
FDA Modifies Dosage Regimen for Nivolumab
On September 13, 2016, the U.S. Food and Drug Administration (FDA) modified the dosage regimen for nivolumab (Opdivo) for the currently approved indications for renal cell carcinoma, metastatic melanoma, and non–small cell lung cancer (NSCLC). The currently approved recommended dosage...
Similar 10-Year Survival Reported With Active Monitoring, Surgery, or Radiotherapy for PSA-Detected Localized Prostate Cancer
In a UK trial (ProtecT) reported in The New England Journal of Medicine, Hamdy et al found no significant differences in prostate cancer–specific or overall mortality among men with localized prostate cancer detected by prostate-specific antigen (PSA) testing who underwent active monitoring,...
PSA Failure Seems to Be Linked to Poorer Survival in Men With Unfavorable-Risk Prostate Cancer and No/Minimal Comorbidity
In an analysis of a clinical trial population reported in the Journal of Clinical Oncology, Giacalone et al found that prostate-specific antigen (PSA) failure was associated with an increased risk of mortality among men with unfavorable-risk prostate cancer who had no or minimal comorbidity burden. ...
NCI Colorectal Cancer Risk Assessment Tool Estimates Current Risk of Advanced Neoplasia
In a study reported in the Journal of the National Cancer Institute, Imperiale et al found that the National Cancer Institute (NCI) colorectal cancer risk assessment tool was able to estimate the current risk for advanced colorectal neoplasia. Study Details The study involved 4,457 persons aged...
Preclinical Study Finds Tamoxifen Resistance Linked to High Estrogen Levels in Utero
An animal study suggests that resistance to tamoxifen therapy in some estrogen receptor–positive breast cancers may originate from in utero exposure to endocrine-disrupting chemicals. The study provides a new path forward in human research, as about half of the breast cancers treated with...
Shorter Survival Reported With Neoadjuvant Chemotherapy vs Primary Reductive Surgery in Stage IIIC Ovarian Cancer
Neoadjuvant chemotherapy was associated with shorter survival vs primary cytoreductive surgery in patients with stage IIIC ovarian cancer, according to a multi-institute observational study reported by Meyer et al in the Journal of Clinical Oncology. The study involved 1,538 women with stage IIIC...
Improved Quality of Life Reported With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed Multiple Myeloma
As reported in the Journal of Clinical Oncology, Stewart et al found that treatment with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) was associated with improved health-related quality of life vs lenalidomide/dexamethasone (Rd) in relapsed multiple myeloma in the phase...
Autopsy Data Suggest No Increase in Differentiated Thyroid Cancer Over Past Few Decades
The prevalence of incidental differentiated thyroid cancer has remained fairly stable since the 1970s, according to a meta-analysis of autopsy data reported by Furuya-Kanamori et al in the Journal of Clinical Oncology. This finding does not support the reports of manyfold increases in...
Durable Responses Reported With Avelumab in Chemotherapy-Refractory Metastatic Merkel Cell Carcinoma
In a phase II trial reported in The Lancet Oncology, Kaufman et al found that the anti–PD-L1 (programmed cell death ligand 1) monoclonal antibody avelumab produced durable responses in patients with stage IV Merkel cell carcinoma progressing after cytotoxic chemotherapy. Study Details In...
Little Benefit Reported With WBRT in NSCLC Patients With Brain Metastases Unsuitable for Resection or Stereotactic Radiotherapy
In a UK-based phase III noninferiority trial (QUARTZ) reported in The Lancet, Mulvenna et al found that use of whole-brain radiotherapy in addition to optimal supportive care including dexamethasone was associated with little additional benefit in non–small cell lung cancer (NSCLC) patients...
Study Finds HIV Infection Linked to Reduced Survival Among Women With Cervical Cancer in Botswana
Despite access to and use of antiretroviral therapy, HIV (human immunodeficiency virus) infection was associated with reduced survival in women with cervical cancer in Botswana, according to a study reported by Dryden-Peterson et al in the Journal of Clinical Oncology. Study Details The study...
Palliative Care 2016: Usage of Oregon’s Death With Dignity Act
In 1997, Oregon enacted a voter initiative allowing terminally ill residents to self-administer physician-prescribed medication to end their lives called the Oregon Death With Dignity Act (ORDWDA). Statute requires prescriptions written for lethal medications be reported; the state also collects...
Early FDG-PET and Volumetric Analysis May Be Best Predictors of Benefit in Ewing Sarcoma
In a study reported in the Journal of Clinical Oncology, Koshkin et al found that among anatomic and functional imaging modalities, volumetric analysis and outcome with early 18F-fluorodeoxyglucose (FDG)–positron-emission tomography (PET) were the best predictors of benefit in patients with...
Palliative Care 2016: Perception of Curability in Patients With Advanced Cancer Receiving Palliative Care
There are limited data on the illness understanding and perception of curability among patients with advanced cancer receiving palliative care around the world. In a study led by Sriram Yennu, MD, MS, Associate Professor in the Department of Palliative Care and Rehabilitation Medicine at The...
Is Weekly Vinblastine Active in Chemotherapy-Naive Children With Progressive Low-Grade Glioma?
In a phase II Canadian Pediatric Brain Tumor Consortium Study reported in the Journal of Clinical Oncology, Lassaletta et al found that vinblastine monotherapy was associated with response or stable disease in most children with chemotherapy-naive low-grade glioma. Vinblastine monotherapy has shown ...
Study Finds Wide Variation in Breast Density Assessments Among Radiologists
A large observational study examining the variation in breast density assessment among radiologists in clinical practice has found a wide variation—from 6.3% to 84.5%—in the percentage of mammograms rated as showing dense breasts, which persisted after adjusting for patient characteristics. The...
Sriram Yennu, MD, on Patient Perception of Curability
Sriram Yennu, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from a study of an international cohort of patients with advanced cancer who received palliative care. Nearly half the patients incorrectly believed their cancer was curable (Abstract 5).
Limited Access to Radioimmunotherapy in the Community Setting May Lead to Extinction of a Unique Lymphoma Treatment
I am writing to ask the ASCO community for help in addressing a policy decision by the Nuclear Regulatory Commission (NRC) that requires oncologists to take a 700-hour course (on the full range of nuclear medicines) to give one medicine to their patients: prepackaged radioimmunotherapy. It’s...
Hematologic Oncologists Surveyed on Quality Measures of End-of-Life Care
In a study reported in the Journal of Clinical Oncology, Oreofe O. Odejide, MD, MPH, of Dana-Farber Cancer Institute, and colleagues surveyed hematologic oncologists to identify acceptable end-of-life-care quality measures and barriers to such care. Respondents considered unrealistic patient...
Immune Cell Infiltrates May Portend Better Prognosis Across Several Tumor Types
High expression of T-cell and B-cell signatures in infiltrates in the tumor microenvironment predicted improved overall survival across many tumor types, according to a study reported by Iglesia et al in the Journal of the National Cancer Institute. Benjamin Vincent, MD, of UNC (University of North ...
Regorafenib Increases Progression-Free Survival in Advanced Gastric Cancer
The multikinase inhibitor regorafenib (Stivarga) prolonged progression-free survival vs placebo in patients with previously treated advanced gastric carcinoma, in a phase II trial reported in the Journal of Clinical Oncology by Nick Pavlakis, MBBS, PhD, of the University of Sydney, Australia, and...
Cyclophosphamide/Methotrexate Maintenance Shows No Benefit in Hormone Receptor–Negative Breast Cancer, but Subgroup May Benefit
Low-dose oral cyclophosphamide plus methotrexate maintenance therapy yielded no disease-free survival benefit in women with hormone receptor–negative early breast cancer, according to the phase III International Breast Cancer Study Group (IBCSG) 22-00 trial. Some evidence of benefit was observed in ...
Impact of Adherence to Cancer Prevention Guidelines on Diet, Physical Activity on Cancer Risk and Mortality
According to the American Cancer Society’s 2016 Cancer Facts & Figures, behaviors such as poor diet choices, physical inactivity, excess alcohol consumption, and unhealthy body weight account for about 20% of all cancers diagnosed in the United States and likely could be prevented with...
New Appointments to Fox Chase Cancer Center Department of Medicine
Fox Chase Cancer Center recently announced two new appointments in its Department of Medicine. Christopher J. Manley, MD Christopher J. Manley, MD, has joined Fox Chase Cancer Center as the Director of Interventional Pulmonology in the Department of Medicine. “Dr. Manley’s expertise in pulmonary...
ASCO and AACI Collaborate on Initiative to Reduce Administrative and Regulatory Burden in Cancer Clinical Trials
As reported in the Journal of Clinical Oncology, Vose et al have provided a summary of the groundwork of an initiative by ASCO and the Association of American Cancer Institutes (AACI) to identify and reduce administrative and regulatory burdens in the conduct of cancer clinical trials. The...
Media Reports of Dramatic Responses to Immunotherapy After All Else Fails May Prompt Patients to Seek It Out
Immunotherapy has received “a lot of attention, mainly because of the media coverage,” Anas Younes, MD, medical oncologist and Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, said in an interview with The ASCO Post. “Many patients inquire, not about a specific...
Electronic Health Record Data May Help Identify Older Patients at Highest Risk of Early Death From Chemotherapy for Diffuse Large B-Cell Lymphoma
Although diffuse large B-cell lymphoma (DLBCL) is a curable disease in most patients aged 65 years or older, these patients are also at higher risk of chemotherapy-related death within the first 30 days of treatment. To quantify the risk of early fatality and identify risk factors, researchers led ...
Study Suggests Benefit of Adjuvant Radiation Therapy but Not Chemotherapy in Some Patients With Merkel Cell Carcinoma
In an analysis of National Cancer Data Base data reported in the Journal of the National Cancer Institute, Bhatia et al found that adjuvant radiotherapy was associated with a survival benefit in patients with stage I and II but not stage III Merkel cell carcinoma, with no benefit of adjuvant...
I’ve Survived Two Cancers
In 2012, my husband, Robert, and I were looking forward to starting the next phase of our lives and were feeling excited about the future. Although only in our 50s, we had decided to retire early from our full-time careers, move to our cabin in Hayward, Wisconsin, and find less stressful part-time ...
Oncologist’s Guilt
The best part of my day is hearing that little voice yell, “It’s Momma!” as my son rushes to greet me with a hug. It is humbling, and sometimes terrifying, to realize that I brought a little person into the world who is completely dependent on my husband and me for survival. Few would argue...
The Best Oncology Lesson
I was 2 months into my first-year fellowship at Georgetown Lombardi Comprehensive Cancer Center in Washington, DC, when I learned the best oncology lesson of my career. I owned a copy of DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology and had read Cancer Treatment...
